Peptide Therapeutics Market by Technology (Hybrid Phase, Liquid Phase, Solid Phase), Drug Class (Adrenocorticotropic Hormone, Calcitonin, Insulin), Route of Administration, Application, End User, Manufacturing Type - Global Forecast 2024-2030

[181 Pages Report] The Peptide Therapeutics Market size was estimated at USD 33.06 billion in 2023 and expected to reach USD 35.76 billion in 2024, at a CAGR 8.35% to reach USD 57.97 billion by 2030.

Peptide therapeutics use short chains of amino acids to treat or control various diseases and medical conditions. These biologically active molecules possess unique properties, making them an efficient drug development and pharmaceutical research option. The surging prevalence of chronic diseases, including cancer and diabetes, is raising the need for effective treatment options and an improved understanding of protein-protein interactions leading to targeted therapies. The growing investment in research & development activities and a robust clinical pipeline with therapeutic candidates result in novel peptide therapeutics being developed. However, the inherent instability of peptides and the high cost of manufacturing peptides may adversely impact the development of peptide therapeutics. Moreover, recent developments in drug delivery systems and the development of new peptides are expected to expand the potential applications for peptides.

The peptide therapeutics market is evolving in the Americas due to well-established pharmaceutical industries, increased research activities, and a growing number of approved peptide drugs. Patent activity in this region is notable, with several major pharmaceutical companies headquartered in the area. In recent years, investments in innovative peptide formulations have increased, indicating a robust market potential for new therapeutic approaches. The rising prevalence of chronic disease, improving healthcare infrastructure, and growing awareness regarding peptide therapeutics are encouraging the growth of the peptide therapeutics market in the APAC region. In addition, ongoing advancements and the development of efficient, scalable, and cost-effective synthetic strategies for producing peptides are anticipated to encourage the adoption of peptide therapeutics globally. The peptide therapeutics market is developing in the EMEA region owing to the regulatory framework supporting innovation within biotechnology and funding research projects related to peptide therapeutics. The European Union demonstrates a well-established market for peptide therapeutics, supported by comprehensive healthcare systems and a high degree of awareness regarding advanced treatment options. The EU's regulatory framework, through the European Medicines Agency (EMA), has been instrumental in approving and monitoring peptide-based drugs. The peptide therapeutics market in the African region is currently growing steadily, characterized by growing research activities and increasing awareness toward advanced therapeutic options.

The hybrid phase approach combines liquid-phase and solid-phase synthesis features to enhance efficiency and scalability while maintaining high purity levels for peptide production. This technique is favored while developing complex or large peptides due to its ability to overcome challenges associated with traditional methods. Liquid phase peptide synthesis (LPPS) involves coupling amino acids in solution using various chemical reactions. LPPS is suitable for small-scale production of short to medium-length peptides due to its relatively fast reaction rates compared to solid-phase methods. Solid phase peptide synthesis (SPPS) involves attaching the first amino acid to a solid resin support, followed by the sequential addition of subsequent amino acids. This method is widely preferred due to its ability to synthesize longer and more complex peptides and ease of purification and scalability. Hybrid phase technology is preferred for developing large or complex peptides due to its combined advantages from liquid and solid phases. Liquid phase synthesis is primarily used for small-scale, short- to medium-length peptide production. Solid-phase peptide synthesis is widely favored due to its versatility in synthesizing longer and more complex peptides while offering easy purification and scalability options.

Adrenocorticotropic hormone (ACTH) is a polypeptide hormone secreted and produced by the anterior pituitary gland. Therapeutically, ACTH is utilized in managing certain disorders where there is a need to stimulate cortisol production. This includes treatment for conditions such as adrenal insufficiency and certain inflammatory disorders that respond to increased cortisol levels. The exogenous form used in therapy provides a direct stimulus to the adrenal cortex by simulating the action of occurring ACTH, encouraging it to secrete cortisol, thereby exerting anti-inflammatory and immunostimulatory effects. Calcitonin is critical in calcium and phosphorus metabolism. It is produced in humans primarily by the parafollicular thyroid gland cells. Therapeutic forms of calcitonin, derived from salmon or synthetically produced, are utilized primarily in treating postmenopausal osteoporosis, Paget's disease, and hypercalcemia. By inhibiting osteoclast activity, calcitonin reduces bone resorption, thereby decreasing blood calcium levels. Insulin is a fundamental peptide hormone critical for regulating glucose metabolism produced by the beta cells of the pancreas, facilitating glucose uptake from the blood into the muscle, liver, and fat cells. In the therapeutic context, insulin is vital in managing diabetes mellitus, both type 1 and type 2, where the body's ability to produce or respond to insulin is impaired. Leuprorelin is a synthetic analog of gonadotropin-releasing hormone (GnRH) and functions as a potent inhibitor of gonadotropin secretion when used in continuous administration. It is employed in the treatment of hormone-responsive cancers such as prostate cancer in men and endometriosis and uterine fibroids in women. Octreotide is a synthetic octapeptide analog of the natural hormone somatostatin, possessing similar but longer-lasting pharmacological effects. It is primarily used in the management of acromegaly, a condition characterized by excess production of growth hormone, and in the control of symptoms caused by certain types of tumors that secrete hormones, such as carcinoid tumors and vasoactive intestinal peptide-secreting adenomas (VIPomas). Octreotide works by inhibiting the secretion of various hormones, including growth hormone, gastrin, insulin, and glucagon. Vasopressin, also referred to as antidiuretic hormone (ADH), is a peptide hormone that is secreted by the posterior pituitary gland and produced by the hypothalamus. ADH is critical in regulating the body's water retention by increasing water reabsorption in the kidney's collecting ducts. In a therapeutic setting, vasopressin and its analogs are used to treat diabetes insipidus, a condition characterized by excess thirst and the production of large amounts of diluted urine, and for managing variceal bleeding due to its vasoconstrictive properties.

Intravenous (IV) administration of peptide therapeutics ensures direct delivery into the bloodstream, facilitating immediate bioavailability. This route is particularly advantageous for peptides that are poorly absorbed through the gastrointestinal tract or extensively metabolized when administered by other routes. IV administration is critical for peptides used in acute care settings or where rapid onset of action is necessary. However, it requires clinical infrastructure and skilled personnel to administer, potentially limiting its applicability to outpatient settings or chronic treatments. Nasal & pulmonary routes offer non-invasive administration alternatives for peptide therapeutics, capable of providing efficient absorption and immediate action for certain conditions. Nasal administration is particularly suited for peptides targeting the central nervous system, leveraging the nose-to-brain pathway. Pulmonary administration is ideal for peptides intended for respiratory ailments, allowing direct delivery to the lungs. Both methods bypass first-pass metabolism, potentially increasing the therapeutic's bioavailability. Oral administration is a preferred route for drug delivery, attributed to its convenience, patient compliance, and cost-effectiveness. Peptides are subject to enzymatic degradation within the gastrointestinal tract and suffer from poor permeability across the intestinal epithelium. Advances in pharmaceutical sciences, such as enzyme inhibitors, permeation enhancers, and nanoparticle delivery systems, have shown promise in overcoming these hurdles, albeit with varying degrees of success. Transdermal delivery of peptide therapeutics offers a compelling balance between efficacy and patient compliance, eliminating the need for injections or specialized inhalation devices. This route is particularly advantageous for chronic conditions requiring sustained release of medication. Advances in transdermal technologies, including microneedles, iontophoresis, and ultrasound, have improved the transport of peptides across the skin barrier. Formulation strategies that enhance skin permeability and peptide stability are central to the successful development of transdermal peptide therapeutics.

In cardiovascular disorders, peptide therapeutics have been used for their precise mechanisms of action, which can effectively modulate vascular function, blood pressure, and coagulation pathways. Anticoagulant peptides are utilized to prevent thrombosis, a critical risk factor for myocardial infarction and stroke. In gastrointestinal (GI) disorders, peptide therapeutics present an avenue for targeted treatment options. In addition, peptides that mimic or inhibit gastrointestinal hormones can regulate motility, absorption, and secretion within the GI tract, addressing symptoms of various disorders. Their targeted action can aid in managing conditions stemming from hormonal imbalances or disruptions in GI-related disorders. Peptide therapeutics bring a novel approach to managing infectious disorders, especially in an era of increasing antibiotic resistance. Antimicrobial peptides (AMPs) offer a broad-spectrum antimicrobial activity, targeting bacteria, fungi, and even some viruses by disrupting their cellular membranes. Their mode of action reduces the likelihood of resistance development, making them crucial contenders in the fight against drug-resistant infections. In neurological disorders, peptide therapeutics are being explored for their potential for crossing the blood-brain barrier (BBB) and delivering neuroprotective effects directly to the central nervous system (CNS). Peptides target specific neurotransmitter systems, providing opportunities for the treatment of diseases, including Alzheimer's, Parkinson's, and multiple sclerosis. In oncology, peptide therapeutics represent a fast-growing area, with peptides being investigated for their anti-cancer properties, including direct cytotoxic effects on cancer cells, inhibition of angiogenesis, and vehicles for targeted drug delivery. Tumor-homing peptides are able to selectively deliver chemotherapeutic agents or radionuclides to tumor cells, minimizing damage to healthy tissues and enhancing treatment efficacy.

In hospitals & clinics, peptide therapeutics are primarily utilized for direct patient care. They are employed in treating numerous conditions, including cancer, metabolic disorders, cardiovascular diseases, and infectious diseases. Peptide drugs offer a targeted approach to treatment due to their high specificity and potency with relatively low toxicity, allowing for higher efficacy with potentially fewer side effects compared to traditional small molecule drugs. Their application in hospitals & clinics continuously evolves with advances in peptide engineering and drug delivery technologies, enhancing their effectiveness and patient compliance. Long-term care facilities prioritize treatments that ensure the well-being of patients over extended periods, often focusing on management rather than cure. Peptide therapeutics used in long-term care facilities need to have minimal side effects and require less frequent dosing schedules to accommodate the caregiving environment. Research laboratories are crucial in the early stages of peptide therapeutic development. Researchers focus on identifying new bioactive peptides, elucidating their mechanisms of action, and optimizing their properties for therapeutic use. This involves cutting-edge molecular biology, biochemistry, and pharmacology techniques to design, synthesize, and assess the activity of peptide candidates.

Contract manufacturing organizations provide essential services in the production of peptide therapeutics, serving pharmaceutical and biotech companies that either do not possess the necessary in-house production facilities or choose to outsource manufacturing to focus on core competencies. CMOs offer various services, from synthesizing peptides in small quantities for research purposes to large-scale production for commercial use. They possess the technical expertise, advanced technologies, and regulatory knowledge required for the efficient and compliant manufacture of peptide therapeutics. In-house production refers to the scenario where pharmaceutical or biotechnology companies have the facilities and resources to manufacture peptide therapeutics. This approach allows companies to maintain direct control over the production processes, quality control, and supply chain management, potentially reducing risks associated with reliance on external suppliers. Large pharmaceutical companies often establish in-house production facilities with the financial resources to invest in the necessary infrastructure and skilled personnel. This model facilitates closer integration between research and development activities and manufacturing, which can be advantageous in rapidly evolving therapeutic areas.

The market dynamics represent an ever-changing landscape of the Peptide Therapeutics Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

The market disruption analysis delves into the core elements associated with market-influencing changes, including breakthrough technological advancements that introduce novel features, integration capabilities, regulatory shifts that could drive or restrain market growth, and the emergence of innovative market players challenging traditional paradigms. This analysis facilitates a competitive advantage by preparing players in the Peptide Therapeutics Market to pre-emptively adapt to these market-influencing changes, enhances risk management by early identification of threats, informs calculated investment decisions, and drives innovation toward areas with the highest demand in the Peptide Therapeutics Market.

The porter's five forces analysis offers a simple and powerful tool for understanding, identifying, and analyzing the position, situation, and power of the businesses in the Peptide Therapeutics Market. This model is helpful for companies to understand the strength of their current competitive position and the position they are considering repositioning into. With a clear understanding of where power lies, businesses can take advantage of a situation of strength, improve weaknesses, and avoid taking wrong steps. The tool identifies whether new products, services, or companies have the potential to be profitable. In addition, it can be very informative when used to understand the balance of power in exceptional use cases.

The value chain of the Peptide Therapeutics Market encompasses all intermediate value addition activities, including raw materials used, product inception, and final delivery, aiding in identifying competitive advantages and improvement areas. Critical path analysis of the <> market identifies task sequences crucial for timely project completion, aiding resource allocation and bottleneck identification. Value chain and critical path analysis methods optimize efficiency, improve quality, enhance competitiveness, and increase profitability. Value chain analysis targets production inefficiencies, and critical path analysis ensures project timeliness. These analyses facilitate businesses in making informed decisions, responding to market demands swiftly, and achieving sustainable growth by optimizing operations and maximizing resource utilization.

The pricing analysis comprehensively evaluates how a product or service is priced within the Peptide Therapeutics Market. This evaluation encompasses various factors that impact the price of a product, including production costs, competition, demand, customer value perception, and changing margins. An essential aspect of this analysis is understanding price elasticity, which measures how sensitive the market for a product is to its price change. It provides insight into competitive pricing strategies, enabling businesses to position their products advantageously in the Peptide Therapeutics Market.

The technology analysis involves evaluating the current and emerging technologies relevant to a specific industry or market. This analysis includes breakthrough trends across the value chain that directly define the future course of long-term profitability and overall advancement in the Peptide Therapeutics Market.

The patent analysis involves evaluating patent filing trends, assessing patent ownership, analyzing the legal status and compliance, and collecting competitive intelligence from patents within the Peptide Therapeutics Market and its parent industry. Analyzing the ownership of patents, assessing their legal status, and interpreting the patents to gather insights into competitors' technology strategies assist businesses in strategizing and optimizing product positioning and investment decisions.

The trade analysis of the Peptide Therapeutics Market explores the complex interplay of import and export activities, emphasizing the critical role played by key trading nations. This analysis identifies geographical discrepancies in trade flows, offering a deep insight into regional disparities to identify geographic areas suitable for market expansion. A detailed analysis of the regulatory landscape focuses on tariffs, taxes, and customs procedures that significantly determine international trade flows. This analysis is crucial for understanding the overarching legal framework that businesses must navigate.

The regulatory framework analysis for the Peptide Therapeutics Market is essential for ensuring legal compliance, managing risks, shaping business strategies, fostering innovation, protecting consumers, accessing markets, maintaining reputation, and managing stakeholder relations. Regulatory frameworks shape business strategies and expansion initiatives, guiding informed decision-making processes. Furthermore, this analysis uncovers avenues for innovation within existing regulations or by advocating for regulatory changes to foster innovation.

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Peptide Therapeutics Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Peptide Therapeutics Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

• Expansion of GMP Capacities at CordenPharma Frankfurt: Elevating Early-Phase Peptide API Manufacturing

  CordenPharma introduced new GMP capacities at its Frankfurt site, marking a significant step in its ongoing efforts to support early clinical phase drug development. Slated for full operational readiness in Q2 2024 with authorization from German authorities expected in H2 2024, this expansion adds 1000 m² of manufacturing space featuring cutting-edge Solid Phase Peptide Synthesis (SPPS) and High-Pressure Liquid Chromatography (HPLC), among other technologies. This initiative highlights CordenPharma’s commitment to integrated service offerings, linking Peptide Drug Substance production in Frankfurt with Injectable Drug Products in Caponago (Italy), thus facilitating efficient Investigational New Drug (IND) / Investigational Medicinal Product Dossier (IMPD) submissions and the initiation of First In-Human (FIH) clinical trials. [Published On: 2024-03-06]

• Revolutionizing Peptide Therapeutics: Orbis Medicines Innovates for Oral Drug Delivery

  Orbis Medicines emerged from stealth mode, indicating an advanced step in the field of peptide therapeutics with a substantial EUR 26 million seed funding led by Novo Holdings and Forbion. The company is at the forefront of developing peptide-based drugs that can be administered orally, offering a promising alternative to the conventional, and often burdensome, injectable biologics used for chronic conditions. The platform employs highly automated chemical synthesis and screening processes, accelerated by machine learning techniques, to rapidly produce potential drug candidates optimized for oral administration. [Published On: 2024-02-29]

• Expanding Facilities in Peptide Therapeutic Production: WuXi AppTec's Strategic Growth

  WuXi AppTec advanced its manufacturing capabilities with the opening of two new peptide manufacturing facilities, located at Changzhou and the newly established Taixing site in Jiangsu, China. This expansion significantly enhanced the company’s Solid-Phase Peptide Synthesis (SPPS) capabilities, increasing its total reactor volume to 32,000 liters. Leveraging state-of-the-art digital operation systems, these facilities are equipped with automated solvent delivery mechanisms designed to optimize production consistency, reduce cycle times, and minimize human error. [Published On: 2024-01-08]

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Peptide Therapeutics Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

The report delves into recent significant developments in the Peptide Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AmbioPharm, Inc., Amgen Inc., Amide Technologies, Inc., AstraZeneca PLC, Bachem Holding AG, Biosynth Ltd., Bristol Myers Squibb Company, Cidara Therapeutics, Inc., Corden Pharma International GmbH, Cybrexa, Inc., Eccogene, Eli Lilly and Company, Exelixis, Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Ipsen Group, IRBM S.p.A., Ironwood Pharmaceuticals, Inc., Merck KGaA, Novartis AG, Novo Nordisk A/S, Otsuka Pharmaceutical Co., Ltd., Peptidream Co., Ltd., Perpetual Medicines Corporation, Pfizer Inc., Piramal Pharma Limited, PolyPeptide Group AG, RELIEF THERAPEUTICS Holding SA, Sanofi S.A., Sanyou Biopharmaceuticals Co., Ltd., Shanghai Full-Life Technologies Co, Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Limited, WuXi AppTec Co., Ltd., and Zealand Pharma A/S.

This research report categorizes the Peptide Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Technology
  • Hybrid Phase
  • Liquid Phase
  • Solid Phase
• Drug Class
  • Adrenocorticotropic Hormone
  • Calcitonin
  • Insulin
  • Leuprorelin
  • Octreotide
  • Vasopressin
• Route of Administration
  • Intravenous Administration
  • Nasal & Pulmonary Administration
  • Oral Administration
  • Transdermal Administration
• Application
  • Cardiovascular Disorders
  • Gastrointestinal Disorders
  • Infectious Disorders
  • Neurological Disorders
  • Oncology
• End User
  • Hospitals & Clinics
  • Long-term Care Facilities
  • Research Laboratories
• Manufacturing Type
  • Contract Manufacturing Organization
  • In-house

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • Indiana
      • Maryland
      • Massachusetts
      • Minnesota
      • New Jersey
      • New York
      • North Carolina
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

1. Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
2. Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
3. Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
4. Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
5. Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.

1. What is the current market size and projected growth?
2. Which products, segments, applications, and regions offer promising investment opportunities?
3. What are the prevailing technology trends and regulatory frameworks?
4. What is the market share and positioning of the leading vendors?
5. What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?